Literature DB >> 8291442

Immunohistochemistry of neuronal inclusions in the cerebral cortex and brain-stem in Lewy body disease.

T Fukuda1, J Tanaka, K Watabe, R T Numoto, M Minamitani.   

Abstract

Three cases of Lewy body disease were investigated in order to compare the morphological and immunohistochemical characteristics of the neuronal inclusions in the cerebral cortex (CC) and brain-stem (BS). Ultrastructurally, the CC contained intermediate-sized filaments with variable amounts of granular material and other organelles, whereas the BS consisted of an electron-dense core and an outer area with radially oriented filaments. The cerebral cortex was immuno-reactive with antibodies against tyrosine hydroxylase (TH) and tau protein, and differed from BS. In addition, although the CC were antigenically similar to BS in their neurofilament (70, 160 and 200 kDa) and ubiquitin contents, the localization of neurofilament immunoreactivity differed between them, being confined positively to the core of CC, but to the periphery of the BS. Although Lewy bodies (LB) in idiopathic Parkinson's disease are morphologically similar to BS, they have been reported to differ in their immunoreactivity with antibodies against tau. It has been reported that CC differ from LB with regard to immunoreactivity with antibodies against TH and tropomyosin. It is inferred that these inclusions (CC, BS and LB) differ in morphogenesis.

Entities:  

Mesh:

Year:  1993        PMID: 8291442     DOI: 10.1111/j.1440-1827.1993.tb03230.x

Source DB:  PubMed          Journal:  Acta Pathol Jpn        ISSN: 0001-6632


  8 in total

Review 1.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

2.  Familial encephalopathy with neuroserpin inclusion bodies.

Authors:  R L Davis; P D Holohan; A E Shrimpton; A H Tatum; J Daucher; G H Collins; R Todd; C Bradshaw; P Kent; D Feiglin; A Rosenbaum; M S Yerby; C M Shaw; F Lacbawan; D A Lawrence
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  14-3-3zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria.

Authors:  Jian Wang; Haiyan Lou; Courtney J Pedersen; Amanda D Smith; Ruth G Perez
Journal:  J Biol Chem       Date:  2009-03-16       Impact factor: 5.157

Review 4.  Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.

Authors:  Dena A M Amer; G Brent Irvine; Omar M A El-Agnaf
Journal:  Exp Brain Res       Date:  2006-05-30       Impact factor: 1.972

5.  Lewy bodies.

Authors:  Clifford W Shults
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-31       Impact factor: 11.205

6.  Intraneuronal dopamine-quinone synthesis: a review.

Authors:  D Sulzer; L Zecca
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

7.  Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease.

Authors:  Min Jeong Park; Sang-Myung Cheon; Hye-Ran Bae; Sang-Ho Kim; Jae Woo Kim
Journal:  J Clin Neurol       Date:  2011-12-29       Impact factor: 3.077

8.  CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation.

Authors:  Kyu Hwan Shim; Min Ju Kang; Jee Won Suh; Jung-Min Pyun; Nayoung Ryoo; Young Ho Park; Young Chul Youn; Jae-Won Jang; Jee Hyang Jeong; Kyung Won Park; Seong Hye Choi; Kyoungho Suk; Ho-Won Lee; Pan-Woo Ko; Chan-Nyoung Lee; Tae-Sung Lim; Seong Soo A An; SangYun Kim
Journal:  Alzheimers Res Ther       Date:  2020-07-13       Impact factor: 6.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.